Michel Delforge

Prof. Dr. Michel Delforge

Department of Hematology, University Hospital Leuven, Leuven, Belgium
orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 January 2018 in Journal of Hematology & Oncology
Verified
Journal Article
Open access
PDF file
JCJo Caers
Jo Caers
Bruno David Lourenco PaivaBruno David Lourenco Paiva
Bruno David Lourenco Paiva
Elena ZamagniElena Zamagni
Elena Zamagni
XLXavier LELEU
Xavier LELEU
Joan BladéJoan Bladé
Joan Bladé
LRLaura Rosiñol
Laura Rosiñol
Solitary plasmacytoma is an infrequent form of plasma cell dyscrasia that presents as a single mass of monoclonal plasma cells, located either extramedullary or intraosseous. In some patients, a bone marrow aspiration can detect a low monoclonal plasma cell infiltration which indicates a high risk of early progression to an overt myeloma disease. Before treatment initiation, whole body positron emission tomography–computed tomography or magnetic resonance imaging should be performed to exclude the presence of additional malignant lesions. For decades, treatment has been based on high-dose radiation, but studies exploring the potential benefit of systemic therapies for high-risk patients are urgently needed. In this review, a panel of expert European hematologists updates the recommendations on the diagnosis and management of patients with solitary plasmacytoma.

1 November 2010 in The Lancet Oncology
Verified
Journal Article
Closed access
Michel DelforgeMichel Delforge
Michel Delforge
JBJoan Bladé
Joan Bladé
Meletios-Athanasios DimopoulosMeletios-Athanasios Dimopoulos
Meletios-Athanasios Dimopoulos
TFThierry Facon
Thierry Facon
MKMartin Kropff
Martin Kropff
PSPieter Sonneveld
Pieter Sonneveld

13 March 2015 in Haematologica
Verified
Journal Article
Open access
PDF file
Michel DelforgeMichel Delforge
Michel Delforge
LML. Minuk
L. Minuk
JEJ.-C. Eisenmann
J.-C. Eisenmann
BAB. Arnulf
B. Arnulf
LCL. Canepa
L. Canepa
TFT. Facon
T. Facon
We compared the health-related quality-of-life of patients with newly diagnosed multiple myeloma aged over 65 years or transplant-ineligible in the pivotal, phase III FIRST trial. Patients received: i) continuous lenalidomide and low-dose dexamethasone until disease progression; ii) fixed cycles of lenalidomide and low-dose dexamethasone for 18 months; or iii) fixed cycles of melphalan, prednisone, thalidomide for 18 months. Data were collected using the validated questionnaires (QLQ-MY20, QLQ-C30, and EQ-5D). The analysis focused on the EQ-5D utility value and six domains pre-selected for their perceived clinical relevance. Lenalidomide and low-dose dexamethasone, and melphalan, prednisone, thalidomide improved patients’ health-related quality-of-life from baseline over the duration of the study across all pre-selected domains of the QLQ-C30 and EQ-5D. In the QLQ-MY20, lenalidomide and low-dose dexamethasone demonstrated a significantly greater reduction in the Disease Symptoms domain compared with melphalan, prednisone, thalidomide at Month 3, and significantly lower scores for QLQ-MY20 Side Effects of Treatment at all post-baseline assessments except Month 18. Linear mixed-model repeated-measures analyses confirmed the results observed in the cross-sectional analysis. Continuous lenalidomide and low-dose dexamethasone delays disease progression versus melphalan, prednisone, thalidomide and has been associated with a clinically meaningful improvement in health-related quality-of-life. These results further establish continuous lenalidomide and low-dose dexamethasone as a new standard of care for initial therapy of myeloma by demonstrating superior health-related quality-of-life during treatment, compared with melphalan, prednisone, thalidomide.

2 March 2011 in European Journal of Haematology
Verified
Journal Article
Closed access
PDF file
Michel DelforgeMichel Delforge
Michel Delforge
ETEvangelos Terpos
Evangelos Terpos
PRPaul G. Richardson
Paul G. Richardson
OSOfer Shpilberg
Ofer Shpilberg
NKNuriet K. Khuageva
Nuriet K. Khuageva
JMJesús F. San Miguel
Jesús F. San Miguel

17 February 2022 in Blood Advances
Verified
Journal Article
Open access
PDF file
Michel DelforgeMichel Delforge
Michel Delforge
NSNina Shah
Nina Shah
JMJesús San F. Miguel
Jesús San F. Miguel
JBJulia Braverman
Julia Braverman
DDDevender S. Dhanda
Devender S. Dhanda
NMNikhil C. Munshi
Nikhil C. Munshi
Idecabtagene vicleucel (ide-cel), a B-cell maturation antigen–directed chimeric antigen receptor T cell therapy, showed deep, durable responses in patients with triple-class exposed, relapsed and refractory multiple myeloma (RRMM) in the phase 2 KarMMa (Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma) trial. We assessed health-related quality of life (HRQoL) among KarMMa patients. The European Organization for Research and Treatment of Cancer Quality of Life C30 Questionnaire and its supplementary 20-item multiple myeloma module, as well as the EuroQol 5-dimension 5-level instrument, were administered at screening, baseline (≤72 hours before or same day as lymphodepletion), day of ide-cel treatment, and after ide-cel treatment. Mean changes from baseline that exceeded the predetermined threshold of minimally important difference were deemed clinically meaningful. The proportions of patients experiencing clinically meaningful changes in HRQoL were assessed using within-patient change thresholds. Time to stable improvement (≥2 consecutive visits with clinically meaningful HRQoL improvements) was analyzed by using the Kaplan-Meier method. A total of 126 (98%) of 128 patients treated with ide-cel were included in the HRQoL analysis. Pretreatment baseline RRMM burden was high and meaningfully worse than that in the age- and sex-weighted general population. Statistically significant and clinically meaningful improvements from baseline were observed by month 1 for pain (−8.9) and disease symptoms (−10.2), and by month 2 for fatigue (−7.2), physical functioning (6.1), cognitive functioning (6.7), and global health status/QoL (8.0). Clinically meaningful improvements in fatigue, pain, and physical functioning were most prominent at months 9, 12, and 18, respectively, and were sustained through 15 to 18 months after ide-cel treatment. For triple-class exposed patients with RRMM with a poor prognosis and few treatment options, a single ide-cel infusion provides early, sustained, statistically significant, and clinically meaningful improvements in HRQoL. This study was registered at Clinicaltrials.gov as #NCT03361748.

3 April 2012 in European Journal of Haematology
Verified
Journal Article
Closed access
PDF file
Michel DelforgeMichel Delforge
Michel Delforge
RDRavinder Dhawan
Ravinder Dhawan
DRDon Robinson
Don Robinson
JMJuliette Meunier
Juliette Meunier
ARAntoine Regnault
Antoine Regnault
JMJesús F. San Miguel
Jesús F. San Miguel